Dependence of electron emission from metals upon field strengths and temperatures

This paper contains a full presentation of the reasons for believing, contrary to results recently obtained elsewhere, that field currents are only independent of temperature up to about 1100°K, and that at that temperature the energy of thermal agitation begins to assist the fields appreciably in causing the escape of electrons from metals. The precise form of function describing this dependence is not accurately determinable experimentally, but the form originally suggested by us fits the facts of observation thus far known satisfactorily, not better, however, than does the theoretical form suggested by Houston

The disintegration of N15 by protons

The absolute cross sections of the reactions (1) N15(p,α)C12, (2) N15(p,αγ)C12, and (3) N15(p,γ)O16 have been measured from 0.2 to 1.6 Mev. The thick target yield of reaction (1) was also measured at 0.100 Mev. Resonances were found at 0.338, 1.05, and 1.210 Mev for reaction (1); at 0.429, 0.898, 1.210, and possibly 1.05 Mev for reaction (2); and at 1.05 Mev for reaction (3). Most of the resonances follow closely the shape of the single level dispersion formula. The 1.05-Mev resonance is asymmetric and cannot be explained as easily. The cross section of reaction (1) has been extrapolated to stellar energies and is given by σ=(110 / E)×exp(-6.95E-1 / 2) barns for E in Mev in the energy region near 0.030 Mev

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy

SIMPLE SUMMARY: The expected change in overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) after the clinical implementation of immune checkpoint inhibitor therapy (ICI) has not been substantially investigated in large real-world cohorts outside randomized controlled trials (RCTs). In this nationwide study, we compared OS before and after the implementation of ICI and found that 3-year OS tripled from 6% to 18%. Patients receiving ICI had a lower OS than demonstrated in RCTs, except for patients with performance status (PS) 0. More than a fifth of the patients progressed early within the first six ICI cycles. Adverse prognostic factors were PS ≥ 1 and metastases to the bone and liver. ABSTRACT: Background The selection of patients with non-small cell lung cancer (NSCLC) for immune checkpoint inhibitor (ICI) treatment remains challenging. This real-world study aimed to compare the overall survival (OS) before and after the implementation of ICIs, to identify OS prognostic factors, and to assess treatment data in first-line (1L) ICI-treated patients without epidermal growth factor receptor mutation or anaplastic lymphoma kinase translocation. Methods Data from the Danish NSCLC population initiated with 1L palliative antineoplastic treatment from 1 January 2013 to 1 October 2018, were extracted from the Danish Lung Cancer Registry (DLCR). Long-term survival and median OS pre- and post-approval of 1L ICI were compared. From electronic health records, additional clinical and treatment data were obtained for ICI-treated patients from 1 March 2017 to 1 October 2018. Results The OS was significantly improved in the DLCR post-approval cohort (n = 2055) compared to the pre-approval cohort (n = 1658). The 3-year OS rates were 18% (95% CI 15.6–20.0) and 6% (95% CI 5.1–7.4), respectively. On multivariable Cox regression, bone (HR = 1.63) and liver metastases (HR = 1.47), performance status (PS) 1 (HR = 1.86), and PS ≥ 2 (HR = 2.19) were significantly associated with poor OS in ICI-treated patients. Conclusion OS significantly improved in patients with advanced NSCLC after ICI implementation in Denmark. In ICI-treated patients, PS ≥ 1, and bone and liver metastases were associated with a worse prognosis

The RAdio Galaxy Environment Reference Survey (RAGERS) : Evidence of an anisotropic distribution of submillimeter galaxies in the 4C 23.56 protocluster at z=2.48

High-redshift radio(-loud) galaxies (H$z$RGs) are massive galaxies with powerful radio-loud active galactic nuclei (AGNs) and serve as beacons for protocluster identification. However, the interplay between H$z$RGs and the large-scale environment remains unclear. To understand the connection between H$z$RGs and the surrounding obscured star formation, we investigated the overdensity and spatial distribution of submillimeter-bright galaxies (SMGs) in the field of 4C\,23.56, a well-known H$z$RG at $z=2.48$. We used SCUBA-2 data ($\sigma\,{\sim}\,0.6$\,mJy) to estimate the $850\,{\rm \mu m}$ source number counts and examine the radial and azimuthal overdensities of the $850\,{\rm \mu m}$ sources in the vicinity of the H$z$RG. The angular distribution of SMGs is inhomogeneous around the H$z$RG 4C\,23.56, with fewer sources oriented along the radio jet. We also find a significant overdensity of bright SMGs (${\rm S}_{850\rm\,\mu m}\geq5\,$mJy). Faint and bright SMGs exhibit different spatial distributions. The former are concentrated in the core region, while the latter prefer the outskirts of the H$z$RG field. High-resolution observations show that the seven brightest SMGs in our sample are intrinsically bright, suggesting that the overdensity of bright SMGs is less likely due to the source multiplicity

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy

Background The selection of patients with non-small cell lung cancer (NSCLC) for immune checkpoint inhibitor (ICI) treatment remains challenging. This real-world study aimed to compare the overall survival (OS) before and after the implementation of ICIs, to identify OS prognostic factors, and to assess treatment data in first-line (1L) ICI-treated patients without epidermal growth factor receptor mutation or anaplastic lymphoma kinase translocation. Methods Data from the Danish NSCLC population initiated with 1L palliative antineoplastic treatment from 1 January 2013 to 1 October 2018, were extracted from the Danish Lung Cancer Registry (DLCR). Long-term survival and median OS pre- and post-approval of 1L ICI were compared. From electronic health records, additional clinical and treatment data were obtained for ICI-treated patients from 1 March 2017 to 1 October 2018. Results The OS was significantly improved in the DLCR post-approval cohort (n = 2055) compared to the pre-approval cohort (n = 1658). The 3-year OS rates were 18% (95% CI 15.6–20.0) and 6% (95% CI 5.1–7.4), respectively. On multivariable Cox regression, bone (HR = 1.63) and liver metastases (HR = 1.47), performance status (PS) 1 (HR = 1.86), and PS ≥ 2 (HR = 2.19) were significantly associated with poor OS in ICI-treated patients. Conclusion OS significantly improved in patients with advanced NSCLC after ICI implementation in Denmark. In ICI-treated patients, PS ≥ 1, and bone and liver metastases were associated with a worse prognosis